Physicians are unimpressed with SNY’s Tzield, according to market-research firm: https://www.prnewswire.com/news-releases/less-than-half-of-endocrinologists-are-impressed-with-tzields-ability-to-delay-t1d-marketvue-report-301874485.html SNY got Tzield in the $2,9B acquisition of PRVB (#msg-171430824).